Norditropin Daily denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare requires prior authorization for Norditropin (daily somatropin) under its Commercial growth hormone policy, and defines an "essential" use of growth hormone as therapy to treat a deficiency as part of chronic disease management, distinguishing it from non-essential replacement uses . Covered indications follow FDA labeling and include Congenital Growth Hormone Deficiency (GHD), Pediatric GHD, Transition Phase Adolescent GHD, Adult GHD, and Prader-Willi Syndrome , with additional pediatric indications such as short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4, and Idiopathic Short Stature (ISS) with height SDS less than -2.25 and growth rates unlikely to permit attainment of adult height in the normal range . Authorization is issued for 12 months at a time , and for transition adolescents the criteria apply during the period from mid to late teens until 6 to 7 years after achievement of adult height . Contraindications per labeling include acute critical illness after open heart or abdominal surgery or multiple accidental trauma, pediatric patients with Prader-Willi syndrome who are severely obese or have upper airway obstruction/sleep apnea, hypersensitivity to somatropin or excipients, and active proliferative or severe non-proliferative diabetic retinopathy . Benefit caps may apply: if the diagnosis is essential the cap is overridden, but if non-essential only the authorization applies and supply limits may be in place . Adult GHD diagnosis typically requires biochemical confirmation (e.g., Insulin Tolerance Test less than 5 ng/mL as the test of choice ) and an endocrinologist must coordinate therapy.

- Submit complete biochemical workup: two failed GH provocative stimulation tests for pediatric GHD per Pediatric Endocrine Society (Grimberg et al., 2016) guidelines, or for adults the Endocrine Society 2011 guideline (Molitch et al.) and AACE/ACE 2019 guideline ( College of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care, Endocr Pract 2019;25(11):1191-1232 ) which support diagnosis with documented pituitary/hypothalamic disease plus low IGF-1 - Provide growth charts demonstrating height SDS and growth velocity, citing Pediatric Endocrine Society guidelines providing recommendations for the clinical management of children and adolescents with growth failure ; if transition-age, cite AACE 2019 transition guidance for retesting - Document open epiphyses by X-ray and ongoing growth velocity >2 cm/year, or document clinical reason for slower response (e.g., late puberty), aligned with Pediatric Endocrine Society recommendations - Confirm prescription is written or co-managed by a board-certified endocrinologist with attestation letter - Demonstrate that contraindications do not apply (e.g., negative sleep study and BMI documentation for PWS patients, ophthalmologic clearance for diabetics, no active neoplasm) per Norditropin prescribing information - Argue essential-use designation: GHD as replacement for a chronic pituitary disease meets UHC's own definition of "therapy to treat a deficiency as part of chronic disease management" , which should override benefit caps - For adult continuation, submit IGF-1 normalization, improvement in body composition, lipid profile, and quality-of-life scores (AGHDA) supporting clinical benefit per Endocrine Society guideline ( Molitch ME et al., Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab )

## Why UnitedHealthcare Requires Step Therapy for Norditropin

Step therapy (also called "fail-first") for somatropin means that UnitedHealthcare requires documentation showing that the patient has first tried — and had an inadequate response to, or could not tolerate — one or more preferred formulary somatropin products before Norditropin will be covered. The denial reflects UHC's formulary management policy rather than a clinical judgment that Norditropin is inappropriate for your patient.

## Why This Denial Is Appealable

Step-therapy requirements are subject to exception under both federal law and the laws of many states. Federal protections (including 21st Century Cures Act step-therapy requirements applicable to Medicare Advantage, and several state step-therapy laws that apply to commercial plans) establish that a step-therapy exception must be granted when: the required step agent is contraindicated, the patient has previously tried and failed it, the patient is clinically stable on the current therapy, or the step requirement would cause clinically significant harm. Even where state law does not apply, UHC's own policies typically include exception pathways — and these are appealable if wrongly denied.

## Federal Appeal Framework

• Step-therapy exception request: File this before or alongside any formal internal appeal.
• Internal appeal: Under ERISA §503 and ACA §2719, a step-therapy denial is an adverse benefit determination subject to full-and-fair internal review.
• External review: An IRO review is available after exhausting internal appeal. The general external-review window is four months from the denial date. The IRO assesses whether the step-therapy protocol was applied correctly and whether exception criteria are met.
• Expedited review: If a delay in access to Norditropin poses a significant health risk, request expedited review.

## Concrete Appeal Steps and Timeline

1. Identify from the denial letter exactly which somatropin product(s) UHC requires you to try first. 2. Review the patient's history: has the patient already tried one or more of those products? Document dates, doses, outcomes, and reasons for discontinuation. 3. Identify whether any exception ground applies: prior failure, intolerance, clinical contraindication, clinical stability on Norditropin, or clinical urgency. 4. Have your prescriber write a letter invoking the applicable exception ground with supporting chart documentation. 5. File the step-therapy exception request, then the internal appeal if the exception is denied. 6. Escalate to external review as needed.

## Documentation to Gather

• Step-therapy history: A written summary of each required step agent the patient tried, with start/end dates, outcome, and reason for discontinuation (adverse effect, inadequate response, or clinical contraindication).
• Clinical stability documentation: If the patient is currently stable on Norditropin (e.g., started under a sample or prior plan), document the clinical response and the risk of switching.
• Prescriber exception letter: Cites the specific exception ground (prior failure, contraindication, stability, urgency), references the chart evidence, and states that requiring the step agent(s) would not be clinically appropriate.
• Chart notes: Office visit notes, lab monitoring results, and any adverse-reaction documentation related to step agents.
• Applicable state law reference: If your state has a commercial-plan step-therapy exception law, cite it in the appeal — your state insurance department website lists applicable statutes.

## Criteria-Mapping Structure

Obtain UHC's step-therapy exception criteria and map each to chart evidence:

| Step-Therapy Exception Criterion | Supporting Chart Evidence | |---|---| | [Copy criterion verbatim from UHC policy or denial letter] | [Date, drug name, outcome, prescriber note] |

A clear prior-failure or clinical-stability argument, well-documented, is among the strongest appeals in the growth hormone space.